Esperion Therapeutics, Inc.
ESPR
$3.14
-$0.01-0.32%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -25.20M | 61.83M | -31.33M | -12.73M | -40.46M |
| Total Depreciation and Amortization | 27.00K | 26.00K | 26.00K | 27.00K | 26.00K |
| Total Amortization of Deferred Charges | 589.00K | 641.00K | 847.00K | 820.00K | 699.00K |
| Total Other Non-Cash Items | -2.09M | 4.07M | 5.21M | 6.77M | 5.07M |
| Change in Net Operating Assets | -1.06M | -21.33M | 20.97M | -26.31M | 12.03M |
| Cash from Operations | -27.72M | 45.24M | -4.29M | -31.42M | -22.63M |
| Capital Expenditure | -189.00K | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -189.00K | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -54.91M | -- | -- | -- |
| Issuance of Common Stock | 16.22M | 84.83M | 10.67M | 2.85M | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 244.00K | 0.00 | 0.00 | -7.50M |
| Cash from Financing | 16.22M | 30.16M | 10.67M | 2.85M | -7.50M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -11.69M | 75.41M | 6.39M | -28.57M | -30.13M |